KRYSKrystal Biotech
About Krystal Biotech
Krystal Biotech (NASDAQ:KRYS) is a focused biotechnology company dedicated to developing and commercializing gene therapies for patients with serious skin diseases. Their innovative approach utilizes a proprietary gene delivery platform aiming to treat conditions with significant unmet needs. Key projects include lead candidate VYJUVEK™, designed to treat dystrophic epidermolysis bullosa, a rare and often fatal skin disorder, showcasing their dedication to transforming the treatment landscape for dermatological conditions. With a mission centered on improving patients' lives by leveraging cutting-edge science, Krystal Biotech is committed to advancing a pipeline of novel gene therapy candidates through clinical development and towards commercial readiness, prioritizing safety, efficacy, and accessibility for those in need.
What is KRYS known for?
Snapshot
Public US
Ownership
2015
Year founded
230
Employees
Pittsburgh, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Pittsburgh, US
Produtos e/ou serviços de Krystal Biotech
- VYJUVEK (beremagene geperpavec, B-VEC) for dystrophic epidermolysis bullosa, the first FDA-approved gene therapy offering hope for this rare skin disorder's effective treatment.
- KB105 for treating TGM-1 deficient autosomal recessive congenital ichthyosis, a therapy under development aimed at addressing severe skin barrier defects through gene replacement.
- KB104, a gene therapy candidate for Netherton Syndrome, focuses on delivering a functional SPINK5 gene to skin cells, aiming to restore the skin's barrier function.
- KB407 for Cystic Fibrosis, which seeks to provide a gene-based treatment to correct the underlying CFTR gene defect in lung epithelial cells, offering a novel approach to this lung disease.
- KB301 for skin rejuvenation and the treatment of fine lines and wrinkles, a novel aesthetic product aiming to promote collagen production and enhance dermal regeneration.
- KB314 for hyperhidrosis, targeting the condition's root cause through gene therapy to offer a long-term solution for excessive sweating without the need for repeat treatments.
equipe executiva do Krystal Biotech
- Mr. Krish S. Krishnan M.B.A., M.S.Founder, Chairman, President & CEO
- Ms. Suma M. KrishnanFounder, President of R&D and Director
- Ms. Kathryn A. Romano CPAExecutive VP & Chief Accounting Officer
- Mr. John ThomasGeneral Counsel & Corporate Secretary
- Mr. John KarakkalVice President of North American Sales & Marketing
- Ms. Christine WilsonHead of U.S. Sales & Marketing
- Dr. Stephane Paquette Ph.D.Vice President of Corporate Development
- Mr. Josh SuskinSenior Director & Head of US Human Resources
- Mr. Laurent GouxSenior VP & GM of Europe
- Dr. David Chien M.D.Senior Vice President of Clinical Development